Humacyte, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-12: Disclosure Material Terms Of Trading Arrangement; Period 2026-04-01..2026-06-30; Value Director and Officer Trading Arrangements On June 3, 2026 , Laura E. Niklason , the Company’s President and Chief Executive Officer , adopted a trading arrangement for the sale of Common Stock that is intended to satisfy the affirmative defense conditions provided by Rule 10b5-1(c) under the Exchang….
- 2026-08-12: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-12: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-12: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-12 10-Q | Material Terms Of Trading Arrangement | 2026-04-01..2026-06-30 | Director and Officer Trading Arrangements On June 3, 2026 , Laura E. Niklason , the Company’s President and Chief Executive Officer , adopted a trading arrangement for the sale of Common Stock that is intended to satisfy the affirmative defense conditions provided by Rule 10b5-1(c) under the Exchang… | |
| 2026-08-12 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-12 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-12 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-12 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-13 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-13 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-28 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-28 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | The timing of annual equity compensation award grants has been generally consistent, with equity grants being made at the regularly scheduled meetings of our Compensation Committee and the Board. Our Board makes annual equity compensation grants to our non-employee directors at the first Board meeti… | |
| 2026-04-28 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-28 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | we typically make employee equity grants in December or January of each year to allow management and the Compensation Committee to review all elements of compensation at the same point in the year. | |
| 2026-04-28 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | No | |
| 2026-04-28 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-04-28 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | Pay Versus Performance As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K (“Item 402(v)”), we are providing the following information about the relationship between executive compensation actually paid ("CAP"), … | |
| 2026-04-28 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | Year Reported Summary Compensation Table Total for PEO ($) Grant Date Fair Value of Awards Granted During the Year Included in SCT Total (a) ($) Year-end Fair Value of Equity Awards Granted During the Year Outstanding and Unvested at Year-end ($) Change in Fair Value During the Year of Equity Awards… | |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$4.33M |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $818.83K |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$1.71M |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$734.90K |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $0.00 |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $0.00 |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $1.47M |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $525.51K |
| 2026-04-28 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | Year Average Reported Summary Compensation Table Total for Non-PEO NEOs ($) Average Grant Date Fair Value of Awards Granted During the Year Included in SCT Total (a) ($) Average Year-end Fair Value of Equity Awards Granted During the Year Outstanding and Unvested at Year-end ($) Average Change in Fa… | |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$1.40M |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $445.30K |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$590.93K |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$273.95K |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $506.60K |
| 2026-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $254.39K |
| 2026-04-28 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | Relationship Between Compensation Actually Paid and Total Shareholder Return As reflected in the Pay Versus Performance table above, the Company’s TSR decreased from $177.82 at December 31, 2024 to $33.80 at December 31, 2025. CAP to the PEO and the average CAP to the Non-PEO NEOs also decreased in … | |
| 2026-04-28 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | Relationship Between Compensation Actually Paid and Net Loss As reflected in the Pay Versus Performance table above, the Company’s net loss improved from $148.7 million in 2024 to $40.8 million in 2025. The Company does not use net loss as a direct measure in determining compensation for its NEOs, b… | |
| 2026-03-27 10-K | Material Terms Of Trading Arrangement | 2025-01-01..2025-12-31 | On October 13, 2025 , Laura E Niklason , the Company’s President and Chief Executive Officer , had a previously disclosed trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act automatically terminate in accordance with its terms upon the … | |
| 2026-03-27 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-27 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-27 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-27 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-27 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2025-11-12 10-Q | Non Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-12 10-Q | Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-12 10-Q | Non Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-11-12 10-Q | Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-08-11 10-Q | Non Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-11 10-Q | Non Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-05-13 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-13 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-13 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-05-13 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-04-29 DEF 14A | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2025-04-29 DEF 14A | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | Equity Grant Decisions The timing of annual equity compensation award grants has been generally consistent, with equity grants being made at the regularly scheduled meetings of our Compensation Committee and the Board. Our Board makes annual equity compensation grants to our non-employee directors a… | |
| 2025-04-29 DEF 14A | Award Timing Method | 2024-01-01..2024-12-31 | The timing of annual equity compensation award grants has been generally consistent, with equity grants being made at the regularly scheduled meetings of our Compensation Committee and the Board. Our Board makes annual equity compensation grants to our non-employee directors at the first Board meeti… | |
| 2025-04-29 DEF 14A | Award Timing Predetermined | 2024-01-01..2024-12-31 | Yes | |
| 2025-04-29 DEF 14A | Award Timing How MNPI Considered | 2024-01-01..2024-12-31 | We do not have any program, plan or practice to time grant dates of equity compensation awards to our executive officers or other employees in coordination with the release of material nonpublic information. | |
| 2025-04-29 DEF 14A | Award Timing MNPI Considered | 2024-01-01..2024-12-31 | No | |
| 2025-04-29 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2024-01-01..2024-12-31 | No | |
| 2025-03-31 10-K | Non Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-03-31 10-K | Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-03-31 10-K | Non Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-03-31 10-K | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2024-11-08 10-Q | Non Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-11-08 10-Q | Non Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-11-08 10-Q | Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-08-13 10-Q | Non Rule10b51Arr Adopted | 2024-04-01..2024-06-30 | No | |
| 2024-08-13 10-Q | Rule10b51Arr Terminated | 2024-04-01..2024-06-30 | No | |
| 2024-08-13 10-Q | Non Rule10b51Arr Terminated | 2024-04-01..2024-06-30 | No | |
| 2024-05-13 10-Q | Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-13 10-Q | Non Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-13 10-Q | Non Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-05-13 10-Q | Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-03-28 10-K | Rule10b51Arr Adopted | 2023-10-01..2023-12-31 | No | |
| 2024-03-28 10-K | Non Rule10b51Arr Adopted | 2023-10-01..2023-12-31 | No | |
| 2024-03-28 10-K | Non Rule10b51Arr Terminated | 2023-10-01..2023-12-31 | No | |
| 2024-03-28 10-K | Rule10b51Arr Terminated | 2023-10-01..2023-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |